Superior response rates and equivalent survival compared to 5-FU/LV in metastatic Colorectal Cancer1-3

• Equivalent survival compared to 5-FU/LV in both studies.1-3
• Pooled median survival: 12.9 months for XELODA vs 12.8 months for 5-FU/LV1-3‡

* Modified from Hoff PM, et al, 2001.1
† Modified from Van Cutsem E, et al, 2001.2
‡ In 2 multicenter, randomized phase III studies of patients previously treated for metastatic Colorectal Cancer.
 

Clinical benefit in nearly 3 of 4 patients treated with XELODA for metastatic Colorectal Cancer1,2

XELODA—Effective fluoropyrimidine foundation to achieve your goals in metastatic Colorectal Cancer treatment4

§ 49.3% of patients treated with 5-FU/LV required dose reductions.2
|| Clinical benefit = CR + PR + SD.
 

REFERENCES

1. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-2292.
2. Van Cutsem E, Twelves C, Cassidy J, et al, for the XELODA Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-4106.
3. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-flourouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. BR J Cancer. 2004;90:1190-1197.
4. O'Shaughnessy J, Miles D, Vukelja S, et al. Supeiror survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002:20(12):2812-2823.